Items where authors include "Earl, HM"

Article

Blagden, SP, Cook, AD, Poole, C et al. (16 more authors) (2020) Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. The Lancet Oncology, 21 (7). pp. 969-977. ISSN 1470-2045

Escala-Garcia, M, Abraham, J, Andrulis, IL et al. (142 more authors) (2020) A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 11 (1). 312.

Clamp, AR, James, EC, McNeish, IA et al. (26 more authors) (2019) Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial. The Lancet, 394 (10214). pp. 2084-2095. ISSN 0140-6736

Dorling, L, Kar, S, Michailidou, K et al. (12 more authors) (2016) The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity: A case-control study. PLoS ONE, 11 (7). ISSN 1932-6203

Adams, M, Calvert, AH, Carmichael, J et al. (20 more authors) (1998) Chemotherapy for ovarian cancer - a consensus statement on standard practice. British Journal of Cancer, 78 (11). pp. 1404-1406. ISSN 0007-0920

Proceedings Paper

Hulme, C, Hall, P, Shinkins, B orcid.org/0000-0001-5350-1018 et al. (5 more authors) (2018) PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Cost effectiveness analysis results. In: Annals of Oncology. ESMO 2018, 19-23 Oct 2018, Munich, Germany. Oxford University Press .